TriangleNCT00565851 · OUTCOME
Progression Free Survival (Surgery Analysis)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Radiographic assessment of disease (in patients with measurable and non-measurable disease) was conducted Every three months for two years and then every 6 months after completion of chemotherapy during the maintenance/surveillance phase.
What was measured
Progression-free survival was defined as the time from randomization to cancer progression as shown on radiography, according to the RECIST version 1.0 criteria, an increase in the CA125 level according to Gynecologic Cancer InterGroup (GCIG) criteria, global deterioration of health, or death from any cause.
Analysis population: All randomized patients who were eligible for the surgery analysis (data were combined and analyzed according to randomized surgical assignment, regardless of chemotherapy regimen, as pre-specified in the study protocol).
Groups in this outcome
No Cytoreductive Surgery
All patients enrolled in the study who did not receive cytoreductive surgery and included in the surgery analysis
Cytoreductive Surgery
All patients enrolled in the study who received secondary cytoreductive surgery and were included in the surgery analysis
| Group | Source count |
|---|---|
| No Cytoreductive Surgery | 245 |
| Cytoreductive Surgery | 240 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| No Cytoreductive Surgery | 16.2 | Not reported | 14.2 | 19.6 | Not reported |
| Cytoreductive Surgery | 18.9 | Not reported | 16.8 | 21.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 14.2
- upper Limit
- 19.6
- value
- 16.2
- group Id
- OG001
- lower Limit
- 16.8
- upper Limit
- 21.0
- value
- 18.9
- denoms
- counts
- group Id
- OG000
- value
- 245
- group Id
- OG001
- value
- 240
- units
- Participants
- description
- Progression-free survival was defined as the time from randomization to cancer progression as shown on radiography, according to the RECIST version 1.0 criteria, an increase in the CA125 level according to Gynecologic Cancer InterGroup (GCIG) criteria, global deterioration of health, or death from any cause.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- All patients enrolled in the study who did not receive cytoreductive surgery and included in the surgery analysis
- id
- OG000
- title
- No Cytoreductive Surgery
- description
- All patients enrolled in the study who received secondary cytoreductive surgery and were included in the surgery analysis
- id
- OG001
- title
- Cytoreductive Surgery
- param Type
- MEDIAN
- population Description
- All randomized patients who were eligible for the surgery analysis (data were combined and analyzed according to randomized surgical assignment, regardless of chemotherapy regimen, as pre-specified in the study protocol).
- reporting Status
- POSTED
- time Frame
- Radiographic assessment of disease (in patients with measurable and non-measurable disease) was conducted Every three months for two years and then every 6 months after completion of chemotherapy during the maintenance/surveillance phase.
- title
- Progression Free Survival (Surgery Analysis)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice